Preclinical mouse models have shown BAFF-R CAR-T cells are capable of killing B-cell lymphoma cells, and notably remain efficacious against malignant B-cells that have lost CD19 antigen expression [44]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.